What is the Clinical Pregnancy Rate of IVF in China? Real Data and Key Factors Affecting Success Rate

The clinical pregnancy rate of IVF in China is influenced by multiple factors such as age, ovarian function, and embryo quality, averaging between 45%-60%. This article provides a detailed analysis from a reproductive medicine perspective of the core indicators affecting pregnancy rates, data differences across age groups, and common misconceptions, helping patients set realistic expectations and approach IVF treatment scientifically.

What is the Clinical Pregnancy Rate of IVF in China? Real Data and Key Factors Affecting Success Rate
IVF 2026-07-14

Opening: Direct Answer

Definition of Clinical Pregnancy Rate and the True Level of IVF in China

The clinical pregnancy rate is a core indicator for evaluating the effectiveness of IVF technology. It refers to the proportion of cases where a gestational sac and fetal heartbeat are observed in the uterine cavity via ultrasound approximately 4–5 weeks after embryo transfer. After years of development, China's assisted reproductive technology has reached an internationally advanced level overall. According to data reported by domestic reproductive medicine centers, between 2020 and 2023, the average clinical pregnancy rate for fresh embryo transfer cycles was approximately 45%–55%, and for frozen-thawed embryo transfer cycles, it was approximately 50%–60%. It is important to clarify that this is a population statistical range; individual pregnancy rates vary significantly due to factors such as patient age, etiology, and embryo status.

Clinical pregnancy rate and live birth rate are two different concepts. After clinical pregnancy, there is still a natural miscarriage risk of about 10%–15%, so the live birth rate is usually lower than the clinical pregnancy rate. The clinical pregnancy rate per single transfer also differs from the cumulative pregnancy rate (the total probability of pregnancy after multiple cycles), with the latter being more valuable for a patient's overall success expectations.

Differences in Clinical Pregnancy Rates Across Age Groups

Age is the most significant factor affecting the clinical pregnancy rate, mainly because the number of eggs decreases with age and the rate of chromosomal abnormalities increases. Female fertility declines more rapidly after age 35, and this decline becomes particularly pronounced after age 40. The following data provides reference ranges for the clinical pregnancy rate per single transfer at different ages from domestic reproductive centers:

Female Age Clinical Pregnancy Rate per Single Transfer (Reference Range) Notes
< 35 years 50% – 65% Can reach the upper limit with normal ovarian reserve
35 – 37 years 40% – 55% Declining quality begins to show
38 – 40 years 30% – 45% Increased rate of chromosomal abnormalities
41 – 42 years 15% – 30% PGT screening is recommended
> 42 years 5% – 15% Egg donation may be more efficient
Data compiled from annual reports of multiple domestic reproductive centers; fluctuations exist due to differences in patient demographics.

From a clinical reproductive medicine perspective, the impact of age on pregnancy rate is mainly reflected in the increased rate of oocyte aneuploidy. The rate of chromosomally normal embryos in women under 35 is about 50%–60%, while it drops to 20%–35% in women over 40. This is why older individuals, even if they obtain morphologically high-scoring embryos, may still experience implantation failure or miscarriage after transfer.

Key Examination Indicators Closely Related to Clinical Pregnancy Rate

The following indicators are important bases for doctors to assess a patient's pregnancy potential and formulate treatment plans, and they directly influence the clinical pregnancy rate:

  • AMH (Anti-Müllerian Hormone) — Reflects ovarian reserve. AMH < 1.0 ng/ml indicates diminished ovarian reserve, potentially leading to fewer eggs retrieved; AMH < 0.5 ng/ml is considered severely low, requiring an individualized ovarian stimulation protocol.
  • Basal FSH (Follicle-Stimulating Hormone) — Measured on day 2–3 of the menstrual cycle. FSH > 10 IU/L suggests reduced ovarian function; FSH > 15 IU/L is often associated with fewer eggs retrieved, fewer embryos, and a lower pregnancy rate.
  • Antral Follicle Count (AFC) — A total antral follicle count in both ovaries < 5–7 indicates reduced ovarian reserve, affecting the number of embryos available for transfer.
  • Endometrial Thickness and Pattern — Endometrial thickness < 7 mm on the day of transfer, or the presence of endometrial polyps, adhesions, adenomyosis, etc., can reduce the embryo implantation rate.
  • Sperm DNA Fragmentation Index (DFI) — DFI > 30% may affect embryo developmental potential and implantation ability, and is a potential cause of recurrent implantation failure.
  • Thyroid Function (TSH) — TSH > 2.5 mIU/L is associated with an increased risk of implantation failure and early miscarriage; it is recommended to keep it below 2.5.
Clinical Tip: Among the above indicators, AMH and AFC mainly affect the number of eggs retrieved, while age and embryo chromosomal normality more directly affect embryo quality. Both need to be evaluated together and should not be viewed in isolation.

Details Most Easily Overlooked That Affect Pregnancy Rate

In clinical practice, the following details are often underestimated by patients and even some doctors, yet they have a substantial impact on pregnancy rates:

  • Insufficient assessment of endometrial receptivity: Adequate endometrial thickness does not equate to normal receptivity. Endometrial microbiota status, chronic endometritis, and local immune microenvironment abnormalities can all interfere with implantation. For patients with recurrent implantation failure, endometrial microbiota testing or CD138 staining for diagnosis is recommended.
  • Neglecting embryo chromosomal normality: Morphologically high-scoring embryos still have a 30%–50% rate of chromosomal abnormalities (increasing with age). PGT technology can screen for chromosomally normal embryos, but it does not increase the clinical pregnancy rate per single transfer; rather, it improves the live birth rate by reducing the miscarriage rate.
  • Inadequate screening for immune factors: Some patients with recurrent implantation failure have immune abnormalities such as elevated NK cell activity, Th1/Th2 imbalance, or lack of blocking antibodies. Targeted immunomodulatory therapy can improve pregnancy outcomes in some patients.
  • Vitamin D levels: Vitamin D deficiency (serum 25(OH)D < 30 ng/ml) is associated with an increased risk of implantation failure and miscarriage. Supplementation to normal levels can help improve pregnancy rates.
  • Incomplete investigation of male factors: Indicators such as sperm DNA fragmentation index and sperm nuclear protein maturity are not reflected in routine semen analysis but directly affect early embryo development.

Common Misconceptions and Pitfalls When Understanding Clinical Pregnancy Rate

When faced with clinical pregnancy rate data, patients are prone to the following cognitive misconceptions, which can affect treatment decisions and mindset:

  • Focusing only on the pregnancy rate per single transfer, ignoring the cumulative pregnancy rate. A single transfer pregnancy rate of 40%–50% may seem low, but after 3–6 cycles, the cumulative pregnancy rate can reach 70%–85%. It is not scientific to pin all hopes on a single transfer.
  • Believing that transferring more embryos is always better. Transferring 2 or more embryos may increase the pregnancy rate per transfer, but it significantly raises the risk of multiple pregnancies, leading to complications such as preterm birth and gestational hypertension. Elective single embryo transfer (eSET) in younger patients can achieve a cumulative pregnancy rate similar to double embryo transfer, with better maternal and infant safety.
  • Excessively pursuing "high success rate" reproductive centers. The "success rates" published by different centers are influenced by factors such as patient age structure, etiology composition, and transfer strategies, making direct comparisons of limited value. When choosing a reproductive center, focus on laboratory quality control, doctor experience, and individualized diagnostic and treatment capabilities, rather than just the numbers.
  • Thinking that PGT (Preimplantation Genetic Testing) can increase the pregnancy rate. The main value of PGT is to screen for chromosomally normal embryos, reducing the miscarriage rate and birth defect rate, but it does not increase the implantation rate per single transfer. For younger patients without a high risk of chromosomal abnormalities, PGT is not a necessary choice.
  • Ignoring the window of endometrial receptivity. In some patients, the endometrial receptive window for the embryo deviates from the usual time (i.e., "displaced implantation window"). Endometrial receptivity analysis (ERA) is needed to determine the optimal timing for transfer.

Case Scenario Analysis: The Path from Failure to Success

📋 Real Case · Anonymized

Patient Profile: 36 years old, AMH 1.8 ng/ml, FSH 9.5 IU/L, with one previous failed IVF attempt. First transfer of a 4AA blastocyst resulted in no pregnancy.

Analysis and Management: The patient's age was not high, AMH was acceptable, and the embryo morphology score was high, but implantation failed. The doctor recommended hysteroscopy + endometrial microbiota testing. A 0.8 cm endometrial polyp was found, along with a low proportion of Lactobacillus in the endometrial microbiota. After polypectomy and antibiotic treatment to adjust the endometrial microbiota, endometrial receptivity was reassessed before the second transfer. A 4BB blastocyst was transferred in a natural cycle, resulting in a successful clinical pregnancy.

Insight: When the clinical pregnancy rate is lower than expected, a systematic investigation of uterine cavity structure, endometrial receptivity, immune, and infectious factors is necessary, rather than blindly repeating transfers. The pregnancy rate can be significantly improved after individualized adjustments.

📋 Common Scenario · Advanced Age with Low Ovarian Reserve

Patient Profile: 41 years old, AMH 0.6 ng/ml, AFC 3, no previous pregnancy history. First ovarian stimulation yielded 2 eggs, forming 1 blastocyst, which did not result in pregnancy after transfer.

Analysis and Management: The patient was of advanced age with low ovarian reserve, resulting in few eggs per retrieval and a high risk of embryo chromosomal abnormalities (estimated >50%). The doctor recommended a cumulative cycle strategy: undergo 2–3 consecutive ovarian stimulation cycles, perform PGT-A screening on all available embryos, and transfer only chromosomally normal embryos. After 3 cycles, a total of 5 blastocysts were obtained, 2 of which were chromosomally normal. Transfer of one resulted in a clinical pregnancy.

Insight: The pregnancy rate per single transfer is low (about 10%–20%) for older individuals with low ovarian reserve. However, through cumulative cycles combined with PGT screening, the cumulative pregnancy rate can be increased to 40%–55%. The key is to establish a reasonable cycle plan rather than expecting success from a single attempt.

A Reproductive Specialist's Perspective: How to View Clinical Pregnancy Rate Rationally

In clinical practice, doctors focus more on individualized patient assessment than on a single success rate number. Here are several core viewpoints from clinical experience:

  • Clinical pregnancy rate is a reference, not a guarantee. No reproductive center or doctor can guarantee success with a single transfer. Patients should focus on modifiable factors (such as weight, thyroid function, vitamin D levels, endometrial status) rather than obsessing over statistics.
  • Cumulative pregnancy rate is more meaningful than single transfer rate. For most patients, as long as transferable embryos can be obtained, the probability of eventual pregnancy after a sufficient number of transfers is quite substantial. Doctors will formulate a reasonable cycle plan based on the patient's ovarian reserve and embryo situation.
  • Individualized protocols are the core of improving pregnancy rates. Ovarian stimulation protocols, trigger timing, embryo culture strategies, transfer timing, and luteal phase support all need to be tailored to the patient's specific situation. Even within the same center, different doctors' protocols can lead to different pregnancy rates.
  • Do not overlook psychological factors. Anxiety, depression, and sleep disorders can affect uterine blood flow and endometrial receptivity through neuroendocrine pathways. Maintaining a relatively stable psychological state during treatment helps support normal physiological functions.
Doctor's Advice: Before starting IVF treatment, complete a comprehensive fertility assessment (including female AMH, FSH, AFC, thyroid function, uterine cavity evaluation, and male semen analysis + DFI), and address any identified issues through pretreatment. This is more practical than simply pursuing a "high success rate" center.

Frequently Asked Questions About Clinical Pregnancy Rate

Q1: How soon can the clinical pregnancy rate result be known?
12–14 days after embryo transfer, a blood test for hCG can provide an initial indication of pregnancy (biochemical pregnancy). 4–5 weeks after transfer, a gestational sac and fetal heartbeat must be visualized in the uterine cavity via ultrasound to confirm a clinical pregnancy. The ultrasound confirmation is typically around 28–30 days after transfer.
Q2: Why do clinical pregnancy rates vary so much between different hospitals?
Reproductive centers differ in patient age composition, etiology distribution, embryo culture technology level, transfer strategies (single vs. double embryo transfer), and statistical methods (fresh vs. frozen embryos). For example, a center primarily treating patients under 35 will naturally have a higher pregnancy rate than one treating mostly patients over 40. It is recommended that patients ask their doctor for data specific to patients of similar age and etiology, rather than directly comparing overall numbers.
Q3: After a first failed transfer, is the success rate higher for a second transfer?
The doctor will adjust the protocol based on the reason for the first failure. If the cause was a uterine cavity issue, abnormal endometrial receptivity, or embryo chromosomal abnormality, targeted treatment may result in a pregnancy rate for the second transfer that is not lower than, or even higher than, the first. However, if the cause is poor ovarian reserve or consistently poor embryo quality, adjusting the stimulation protocol or considering other assisted reproduction methods may be necessary. Overall, after optimization, the cumulative pregnancy rate increases with subsequent transfers.
Q4: Can I still do IVF with low AMH? What is the clinical pregnancy rate?
Low AMH primarily affects the number of eggs retrieved, not egg quality. Egg quality is more closely related to age. If AMH is low but the patient is <35 years old, a reasonable pregnancy rate (40%–55%) is still possible. If AMH is low and the patient is >40 years old, the pregnancy rate per single transfer is typically low (10%–20%). However, through a cumulative cycle strategy, where embryos from multiple cycles are pooled for screening and transfer, the cumulative pregnancy rate can still reach 30%–45%. The key is to develop a reasonable plan for egg retrieval cycles and perform necessary genetic screening on the embryos.
Q5: Does a high sperm DNA fragmentation index affect the clinical pregnancy rate?
Yes. A high sperm DNA fragmentation index (DFI >30%) can affect early embryo development and implantation ability, potentially leading to developmental arrest or miscarriage. Common causes of elevated DFI include varicocele, reproductive tract infections, smoking, and high-temperature environments. DFI can improve in some patients through medication, surgery, or lifestyle adjustments. For patients with persistently high DFI, sperm obtained via testicular sperm aspiration (TESA) usually has better DNA integrity than ejaculated sperm.
⚠️ Risk Reminder and Realistic Expectations

The clinical pregnancy rate is a population statistic and does not represent an individual prognosis. No reproductive center or doctor can guarantee success with a single transfer. Patients should set realistic expectations and understand that IVF may be a process requiring multiple cycles. Age is an irreversible factor. For those with fertility needs who meet the indications for IVF, it is advisable to start treatment at an appropriate age as early as possible to avoid missing the optimal window due to waiting. During treatment, cooperating with the doctor for comprehensive etiological investigation and individualized protocol development is an effective way to improve the pregnancy rate. At the same time, be wary of any institution or individual claiming "guaranteed success" or "100% pregnancy rate," as such promises do not align with the medical ethics and scientific facts of the assisted reproductive industry.

Comments (0)

Leave a Comment